Cu CMM, Alamillo LJ

Language: Spanish
References: 22
Page: 23-27
PDF size: 92.97 Kb.

ABSTRACT

Medulloblastoma is a neuroectodermal origin, is intensely evil and is the most common brain tumor in children between the ages of three to nine years, but the congenital presentation is extremely rare, characterized by hydrocephalus and intracranial hypertension in most of the time. In addition to the age of onset as adverse factor, was added prognostic factors such as maternal history and location of brain stem level which prevented complete resection. Major problems have been associated with lower genetic age of presentation and prognosis remains poor even for these little children, as there are limitations in the treatment due to adverse effects from radiation therapy in immature brains. It is reported of a newborn diagnosed with congenital medulloblastoma confirmed by pathology.

REFERENCES

1. Menon G, Nair S, Muthurethinam T, Krishnakumar K, Bhattacharya RN. Medulloblastoma in children: Prognostic factors and predictors of outcome. J Pediatr Neurosci 2006; 1: 16-20.

2. Rutkowski S, Bode U, Deinlein F, Ottensmeier H, Warmuth-Metz M, Soerensen N et al. Treatment of early childhood medulloblatoma by postoperative chemotherapy alone. N Engl J Med 2005; 352: 978-86.

3. García R, Guillén A, Costa JM. Meduloblastoma, una presentación infrecuente en la recurrencia local. Neurocirugía 2011; 22: 453-6.

4. Manor E, Bodner L. Medulloblastoma-genetic alterations. Molecular Targets of CNS Tumors 2011; 29: 623-38.

5. Komatsu F, Tsugu H, Nonaka M, Tsutsumi M, Yanai F, Yukitake K et al. Congenital medulloblastoma with atypical MRI appearance. Pediatr Neurosurg 2008; 44: 165-8.

6. Kim JH, Duncan C, Manuelidis E. Congenital cerebellar medulloblastoma. Surg Neurol 1985; 23: 75-81.

7. Muñoz JM, De la Cruz J, Sánchez G, Guerrero A, Muñoz JA, Alejo J. Experiencia en el manejo de meduloblastoma en el Servicio de Neurocirugía Pediátrica del Hospital General del Centro Médico Nacional «La Raza». Arch Neurocien 2005; 10(3): 150-5.

8. Poon CC, Lim SM, Hwang WS. Congenital Medulloblastoma. Singapore Med J 1975; 16(3): 230-3.

9. Arakaki N, Diez B, Jaimovich R, Romero C. Imagen del mes. Arch Neurol Neuroc Neuropsiquiatr 2009; 17(1): 53-5.

10. Sarkar C, Deb P, Sharma MC. Medulloblastomas: new directions in risk stratification. Neurol India 2006; 54(1): 16-23.

11. Dufour C, Beaugrand A, Pizer B, Micheli J, Aubelle MS, Fourcade A et al. Metastatic medulloblastoma in childhood: Chang’s classification revisited. Int J Surg Oncol 2012: 1-6.

12. Wael H, Sawy EL. Outcome of children with high-risk medulloblastoma treated with pre-irradiation chemotherapy. J Egyptian Nat Cancer Inst 2001; 13(3): 223-8.

13. Packer RJ, MacDonald T, Vezina G. Central nervous system tumors. Hematol Oncol Clin North Am 2010; 24: 87-108.

14. De Girolami U, Douglas CA, Frosch MP. El sistema nervioso central. En: Robbins y Cotran, Kumar V, Abbas AK, Fausto N. Patología estructural y funcional. Séptima edición. Elsevier, España McGraw-Hill Interamericana; 2006: 1411-12.

15. Hodelín R, Figueredo J, Figueredo R. Meduloblastoma desmoplásico en la infancia. Presentación de tres casos. Rev Cubana de Oncología 1995; 11: 1-3.

16. Partap S, MacLean J, Behren J, Reynolds P, Fisher P. Birth anomalies and obstetric history as risks for childhood tumors of the central nervous system. Pediatrics 2011; 128(3): e652-e7.

17. Parsons W, Li M, Zhang X, Jones S, Leary R, Lin J et al. The genetic landscape of childhood cancer medulloblatoma. Scienc 2011; 331: 435-9.

18. Shim K, Joo SY, Kim SH, Choi JU, Kim DS. Prediction of prognosis in children with medulloblastoma by using immunohistochemical analysis and tissue microarray. J Neurosurg Pediatr 2008; 1: 196-205.

19. Kombogiorgas D, Sgouros S, Walsh A, Hockley A, Stevens M, Grundy R, et al. Outcome of children with posterior fossa medulloblastoma: a single institution experience over the decade 1994-2003. Childs Nerv Syst 2007; 23: 399-405.

20. Zuzak TJ, Rist L, Eggenschwiler J, Grotzer MA, Viviani A. Paediatric medulloblastoma cells are susceptible to viscum album (Mistletoe) preparations. Anticancer Res 2006; 26: 3485-92.

21. Pasqualini T, Alonso G, Diez B, Makiya M, Dibar E. Meduloblastoma: Aspectos endocrinológicos en la evolución alejada en pacientes pediátricos. RAEM 2003; 40(Supl): 180.

22. Rutkowski S, Ulrich N, Hoff K, Gnekon A, Bode U, Graf N et al. Treatment of early childhood medulloblatoma by postoperative chemotherapy and deferred radiotherapy. Neuro-oncology 2009: 201-10.